The White Paper will include:
Key findings from the Pricia White Paper addressing Challenges and Opportunities to address International Reference Pricing present in European healthcare.

The use of International Reference Pricing (IRP) as a cost-containment tool is widely implemented across countries with varying degrees of rule complexity. Despite IRP being argued to cause multiple challenges such as timely patient access, affordability challenges, and a potential impact on pharmaceutical industry sustainability and R&D expenditure.

Our case study shows that significant spillover effects can be expected globally with a large single country price reduction, which require pharmaceutical companies to effectively manage international prices. Integrating IRP assessments through pricing systems in the governance process, establishing a continuously updated IRP library, and breaking down information silos for IRP forecasts were shared as best practices. 

Please fill out the form in order to download our White Paper